Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
60 participants
OBSERVATIONAL
2020-09-07
2023-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Coronary Artery Disease (CAD) in Suppressed HIV-infected
NCT02898896
Utilizing Computed Tomographic Angiography to Evaluate Coronary Artery Disease in Patients on Long-Term Antiretroviral Therapy
NCT02191306
HIV Infection And Evolvement of Atherosclerotic Plaque
NCT04810364
Subclinical Atherosclerosis in HIV-infected Patients
NCT00455793
Inflammation, Viral Replication, and Atherosclerosis in Treated HIV Infection
NCT01519141
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HIV-1 patients and treated effectively for more than 12 months
X-ray examination with contrast by a 64-slice CT coronary angiography.
coronary computed tomographic angiographic (CCTA)
x-ray examination with contrast by a 64-slice CT coronary angiography.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
coronary computed tomographic angiographic (CCTA)
x-ray examination with contrast by a 64-slice CT coronary angiography.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* ATCD of allergy to IV contrast agents
* Chronic inflammatory disease other than HIV
* Subject to a measure for the protection of justice
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hôpital Européen Marseille
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
BENNANI
Marseille, , France
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2019-A00219-48
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.